<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJNeph</journal-id><journal-title-group><journal-title>Open Journal of Nephrology</journal-title></journal-title-group><issn pub-type="epub">2164-2842</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojneph.2021.113029</article-id><article-id pub-id-type="publisher-id">OJNeph-111352</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiological Clinical Profile of Chronic Kidney Disease in Adults under 50 at the University Hospital of Brazzaville
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Daniel</surname><given-names>Tony Eyeni Sinomono</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ginesse</surname><given-names>Ndinga-Okaka Sedan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gael</surname><given-names>Honal Mahoungou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eric</surname><given-names>Pierre Gandzali Ngabe</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Richard</surname><given-names>Moukengue Loumingou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bertrand</surname><given-names>Ellenga-Mbolla</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Arrayhani</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tarik</surname><given-names>Sqalli Houssain</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>Departement of Nephrology, University Hospital Hassan II of Fez, Fez, Morocco</addr-line></aff><aff id="aff2"><addr-line>Hemodialysis Unit of the Medical Center for Specialists of the 15 years old plateau of Brazzaville, Brazzaville, Congo</addr-line></aff><aff id="aff1"><addr-line>Department of Nephrology and Dialysis, University Hospital of Brazzaville, Brazzaville, Congo</addr-line></aff><aff id="aff3"><addr-line>Departement of Nephrology, Edith Lucie Bongo General Hospital of Oyo, Oyo, Congo</addr-line></aff><aff id="aff4"><addr-line>Department of Cardiology and Internal Medicine, University Hospital of Brazzaville, Brazzaville, Congo</addr-line></aff><pub-date pub-type="epub"><day>12</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>358</fpage><lpage>369</lpage><history><date date-type="received"><day>4,</day>	<month>June</month>	<year>2021</year></date><date date-type="rev-recd"><day>16,</day>	<month>August</month>	<year>2021</year>	</date><date date-type="accepted"><day>19,</day>	<month>August</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC).http://creativecommons.org/licenses/by-nc/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Chronic Kidney Disease (CKD) is a major global public health problem. In Congo, we have very few studies on it. 
  Patients and Methods: We carried out an analytical cross-sectional study with retrospective data collection including patients aged 18 to 49 years, hospitalized for CKD in the nephrology department of University Hospital of Brazzaville, during the period from January 1, 2016 to August 31, 2020. The variables considered were socio-demographic, clinical, paraclinical, therapeutic and evolutionary. The statistical test used was Pearson’s chi-square test. 
  Results: CKD in those under 50 represented 21.1% of admissions and 35.6% of CKD. The mean age was 35.9 &#177; 8.4 years. There was a male predominance with a sex ratio of 1.27. Hypertension was the most common comorbidity (49.2%), followed by HIV (13.6%) and diabetes mellitus (13.2%). Stage 5 CKD was most prevalent (82.7%). Indeterminate kidney disease was in the order of 55.9%. The low socioeconomic level (74.9% of cases) hampered the achievement of dialysis in 66.3% of patients for whom this treatment was indicated. Failure to perform dialysis significantly influenced the occurrence of death (p-value = 0.005). 
  Conclusion: CKD is common among people under 50 and more affects males with a high mortality rate due to lack of access to dialysis. The main causes are hypertension and HIV.
 
</p></abstract><kwd-group><kwd>Chronic Kidney Disease</kwd><kwd> Epidemiology</kwd><kwd> Brazzaville</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Chronic Kidney Disease (CKD) represents a significant health challenge in the world population; in both developed and developing countries [<xref ref-type="bibr" rid="scirp.111352-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref3">3</xref>]. At the dialysis stage, it constitutes a real socio-health cost for national health systems. Its prevalence varies greatly from one region to another [<xref ref-type="bibr" rid="scirp.111352-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref4">4</xref>]. It has affected 10% - 15% of the world’s adult population [<xref ref-type="bibr" rid="scirp.111352-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref6">6</xref>]. In Africa, this prevalence is between 30 and 186.5 per million population [<xref ref-type="bibr" rid="scirp.111352-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref8">8</xref>].</p><p>Due to its progressive silent evolution, and its etiologies, dominated by arterial hypertension and diabetes mellitus; CKD is often mistakenly thought of as a disease of the elderly.</p><p>In Sub-Saharan Africa, where the population is mainly made up of young adults [<xref ref-type="bibr" rid="scirp.111352-ref8">8</xref>], the place of CKD among young Sub-Saharan adults remains imprecise due to the lack of scientific data.</p><p>In the Republic of Congo, specifically in Brazzaville, there is very little epidemiological data on the CKD; those produced relate exclusively to chronic renal failure at all ages [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref10">10</xref>]. A study is therefore necessary while placing particular emphasis on the under 50 age group. So we carried out our work with the objectives of: determining the frequency of CKD in adults under 50, describing the socio-demographic, clinical and biological characteristics; identify the etiologies and factors associated with death.</p></sec><sec id="s2"><title>2. Patients and Methods</title><sec id="s2_1"><title>2.1. Type, Place and Period of Study</title><p>This was an analytical cross-sectional study, carried out in the nephrology and dialysis service of the University Hospital of Brazzaville (UHB). The data collection concerned patients hospitalized from January 1, 2016 to August 31, 2020, i.e. 4 years and 8 months.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>We included all patients aged 18 to 49 years, carriers of a CKD, defined independently of its cause by the presence for at least three consecutive months of a marker of renal damage and/or renal insufficiency, defined by a Glomerular Filtration Rate (GFR) less than 60 ml/min/1.73m<sup>2</sup> [<xref ref-type="bibr" rid="scirp.111352-ref5">5</xref>]. Patients with acute kidney disease and those whose medical records were unusable were not included.</p></sec><sec id="s2_3"><title>2.3. Study Variables</title><p>We studied the socio-demographic characteristics (age, sex, marital status, socioeconomic level). The socioeconomic level has been classified into three groups according to professional activities:</p><p>- Group 1: high socio-economic level. These include senior government officials or the private sector, import-export traders, army officers.</p><p>- Group 2: medium socio-economic level. It is made up of agents of the State or the private sector with a level of education equivalent to secondary school, shopkeepers, non-commissioned officers of the army.</p><p>- Group 3: low socio-economic level. It is made up of workers, laborers, farmers, soldiers and the unemployed.</p><p>We have also studied associated comorbidities; the etiologies of CKD; complications, stages based on the staging of KDIGO 2012 [<xref ref-type="bibr" rid="scirp.111352-ref2">2</xref>]; renal replacement techniques, mortality and associated factors.</p></sec><sec id="s2_4"><title>2.4. Collection of Data</title><p>Data were collected from patient medical records and annual hospitalization registers. Anonymity has been retained.</p><p>The data was stored in Excel 2016 software. After the clearance and management of missing data, the analysis was performed in R studio software.</p></sec><sec id="s2_5"><title>2.5. Ethical Clearance</title><p>To carry out our work, we obtained an authorization from the ethics committee of the faculty of health sciences of the Marien Ngouabi University and an authorization from the general management of the UHB.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Main Features</title><p>During our study, 1789 patients were admitted to the nephrology and dialysis department of UHB. CKD was diagnosed in 1061 patients (or 59.3% of admissions) including 378 adults under 50 years, is 21.13% of all admissions and 35.62% of all cases of CKD. Among those under 50; 135 had unusable files. Data could be collected from 243 patients. The socio-demographic characteristics of these patients are shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s3_2"><title>3.2. Co-Morbidities</title><p>High blood pressure is the most common comorbidity at 49.17%, followed by HIV (13.64%) and diabetes mellitus (13.22%). The distribution of patients according to comorbidities is presented in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec><sec id="s3_3"><title>3.3. CKD Stages</title><p>The median serum creatinine was 1145 &#181;mol/L; the median GFR was 4.7 ml/min/ 1.73m<sup>2</sup> (3.1; 9.6). <xref ref-type="table" rid="table3">Table 3</xref> shows the distribution of patients according to the different stages of CKD.</p></sec><sec id="s3_4"><title>3.4. Lesion Diagnosis</title><p>In the context of the lesion diagnosis, in 134 patients (55.14%), the cause remained undetermined while in 109 patients (44.86%), a lesion diagnosis could be determined. <xref ref-type="table" rid="table4">Table 4</xref> shows the distribution of patients according to the lesion diagnosis.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demographic characteristics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle"  colspan="2"  ></th></tr></thead><tr><td align="center" valign="middle" >Average age</td><td align="center" valign="middle"  colspan="2"  >36 &#177; 8.4 years</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Sex</td><td align="center" valign="middle" >Men</td><td align="center" valign="middle" >Women</td></tr><tr><td align="center" valign="middle" >136 (56%)</td><td align="center" valign="middle" >107 (44%)</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Socioeconomic level</td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle"  colspan="2"  >182 (75.0%)</td></tr><tr><td align="center" valign="middle" >Medium</td><td align="center" valign="middle"  colspan="2"  >55 (22.6%)</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle"  colspan="2"  >6 (02.4%)</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comorbidities associated with CKD</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >HBP</td><td align="center" valign="middle" >119</td><td align="center" valign="middle" >49.0</td></tr><tr><td align="center" valign="middle" >HIV</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >21.4</td></tr><tr><td align="center" valign="middle" >Diabetic sugar</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >16.4</td></tr><tr><td align="center" valign="middle" >Heart disease</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >12.0</td></tr><tr><td align="center" valign="middle" >Sickle cell anemia</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >243</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>CKD: chronic kidney disease; HBP: high blood pressure; HIV: human immunodeficiency virus.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Chronic kidney disease stages</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Stage 1</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3.7</td></tr><tr><td align="center" valign="middle" >Stage 2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Stage 3A</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.3</td></tr><tr><td align="center" valign="middle" >Stage 3B</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >3.3</td></tr><tr><td align="center" valign="middle" >Stage 4</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >7.4</td></tr><tr><td align="center" valign="middle" >Stage 5</td><td align="center" valign="middle" >201</td><td align="center" valign="middle" >82.7</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Lesion diagnosis</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle"  rowspan="4"  >Glomerular nephropathies</td><td align="center" valign="middle" >● CGN</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >29.6</td></tr><tr><td align="center" valign="middle" >● Nephrotic syndrom</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >5.3</td></tr><tr><td align="center" valign="middle" >● Glomerular proteinuria isolated</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3.7</td></tr><tr><td align="center" valign="middle" >● Recurrent hematuria</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Tubulointerstitial nephropathies</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.9</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Vascular nephropathies</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >12.3</td></tr></tbody></table></table-wrap><p>CGN: chronic glomerulonephritis.</p></sec><sec id="s3_5"><title>3.5. Etiological Diagnosis</title><p>Renal Biobsia Puncture (RBP) was indicated in 13 patients (5.35%). Two patients did it overseas. While in the 11 other patients it was not done due to lack of technical platform. Histological analysis of the two RBP concluded with segmental and focal hyalinosis. The causes found as well as their proportion are listed in <xref ref-type="table" rid="table5">Table 5</xref>.</p></sec><sec id="s3_6"><title>3.6. Complications of CKD</title><p>Anemia was the main complication of chronic renal failure found in 86% of patients. Apart from patients with stages 1 and 2 of CKD (n = 13), all other patients (n = 230) had at least 2 complications related to chronic renal failure. <xref ref-type="table" rid="table6">Table 6</xref> represents the proportions of each complication found.</p></sec><sec id="s3_7"><title>3.7. Renal Replacement Therapy</title><p>Two hundred and one patients (82.72%) had an indication for dialysis replacement therapy; only 51 of them (25.37%) had done so.</p><p>Peritoneal dialysis was not performed during our study period.</p><p>No patient was transplanted.</p></sec><sec id="s3_8"><title>3.8. Mortality</title><p>Death occurred in 66 patients (27.2%) of which 59 were in stage 5 (24.3%) and seven in stages 1, 2, 3 and 4 (2.9%). <xref ref-type="table" rid="table7">Table 7</xref> presents the different causes of death from CKD and <xref ref-type="table" rid="table8">Table 8</xref> risk factors for death.</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Etiological diagnosis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Indeterminate Hypertensive nephropathy</td><td align="center" valign="middle" >134 38</td><td align="center" valign="middle" >55.1 15.6</td></tr><tr><td align="center" valign="middle" >HIV-related nephropathy</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >13.6</td></tr><tr><td align="center" valign="middle" >Diabetic nephropathy</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >13.2</td></tr><tr><td align="center" valign="middle" >IgA Nephropathy</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Primary segmental and focal hyalinosis</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8</td></tr><tr><td align="center" valign="middle" >Autosomal dominant polycystic kidney disease</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.4</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >243</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>IgA: Immunoglobin A.</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Complications of chronic kidney disease</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Anemia</td><td align="center" valign="middle" >209</td><td align="center" valign="middle" >86</td></tr><tr><td align="center" valign="middle" >Hyperkalaemia</td><td align="center" valign="middle" >103</td><td align="center" valign="middle" >42.4</td></tr><tr><td align="center" valign="middle" >Hyper uricemia</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >8.6</td></tr><tr><td align="center" valign="middle" >Uremic encephalopathy</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >5.3</td></tr><tr><td align="center" valign="middle" >Acute pulmonary edema</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0.8</td></tr><tr><td align="center" valign="middle" >Right femoral venous thrombosis</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.4</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Different causes of death from chronic kidney disease</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Severe acidosis</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >30</td></tr><tr><td align="center" valign="middle" >Uremic encephalopathy</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >22.7</td></tr><tr><td align="center" valign="middle" >Acute pulmonary edema</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >15.6</td></tr><tr><td align="center" valign="middle" >Ischemic heart disease</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.6</td></tr><tr><td align="center" valign="middle" >Severe anemia</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Hemorrhagic stroke</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.5</td></tr><tr><td align="center" valign="middle" >Gastrointestinal bleeding</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Coronavirus (COVID-19)</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Indeterminate</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.6</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Risk factors associated with death</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Total (n =243)</th><th align="center" valign="middle" >Living (n = 177)</th><th align="center" valign="middle" >Deceased (n = 66)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="4"  >Sexe</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Women</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >78</td><td align="center" valign="middle"  rowspan="2"  >0.9</td></tr><tr><td align="center" valign="middle" >Men</td><td align="center" valign="middle" >136</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >99</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Comorbidities</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >HBP</td><td align="center" valign="middle" >119</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >DS</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0.3</td></tr><tr><td align="center" valign="middle" >HIV</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Heart Disease</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="4"  >CKD stages</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >S1</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >1</td><td align="center" valign="middle"  rowspan="5"  >0.5</td></tr><tr><td align="center" valign="middle" >S2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >S3</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >S4</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >S5</td><td align="center" valign="middle" >201</td><td align="center" valign="middle" >143</td><td align="center" valign="middle" >58</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Complications</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hyperkalaemia</td><td align="center" valign="middle" >103</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >0.15</td></tr><tr><td align="center" valign="middle" >APE</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.02</td></tr><tr><td align="center" valign="middle" >Uremic encephalopathy</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Anemia</td><td align="center" valign="middle" >209</td><td align="center" valign="middle" >143</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>CKD: chronic kidney disease; HBP: high blood pressure; HIV: human immunodeficiency virus; APE: Acute pulmonary edema.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Despite the youth of the Sub-Saharan African population, reported by the literature [<xref ref-type="bibr" rid="scirp.111352-ref8">8</xref>], we did not find any studies on CKD carried out exclusively in young adults under the age of 50. We compared our results with those of other studies on CKD at all ages but also with the interval of patients under 50 years if it was mentioned.</p><p>In our study, the CKD represented more than half of hospitalizations in the nephrology department of UHB (59.3%); of which 35.6% were under 50 years old. CKD is therefore common in the latter. Our data join those of Ngoie S.M et al., in Lubumbashi, in 2015 who found a prevalence of 38.3% of CKD among those under 50 years old in the only functional unit of nephrology and dialysis in their city [<xref ref-type="bibr" rid="scirp.111352-ref11">11</xref>].</p><p>However, our frequency, which is admittedly high, is lower than that found by Keylem et al., in 2015, in Ouagadougou (69.6%) [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>]. Sumaili et al. in Kinshasa, in 2009, found a frequency of 89.1% in patients aged 20 to 59 years, of which 58.1% in the 20 to 39 year age group [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. CKD is a reality among young people in Africa. The fact that our monocentric work took place in an intra-hospital ward could explain the frequency, admittedly high, but very far from that found by Sumaili et al. [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>], where the data were multicentric. However, our data as well as those of Ngoie S.M in Lubumbashi remain far from those of Keylem in Ouagadougou, a single-center study carried out over a period of six months [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>]. CKD among those under 50 in Brazzaville is less frequent compared to a country in West Africa. However, these results were inconsistent with those found in developed countries. In fact, in the United States and France, the prevalence of CKD was largely under-represented among those under 50 years of age with respective prevalence of 10.8% and 7.6% [<xref ref-type="bibr" rid="scirp.111352-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref5">5</xref>]. This could be explained by the phenomenon of aging of the larger general population in developed countries, which is a consequence of improving health systems in the West.</p><p>We observed a male predominance (55.97%). This predominance of the male sex in CKD is reported by several studies [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. These data are consistent with those of Sumaili EK. In Kinshasa [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>], the high frequency of CKD in humans is explained by its rapid progression in this area [<xref ref-type="bibr" rid="scirp.111352-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref3">3</xref>]. Our data conflict with that of Ahoui et al. in 2014 in Benin, which reported 51.26% of women (n = 651), i.e. a female/male sex ratio of 0.95 [<xref ref-type="bibr" rid="scirp.111352-ref4">4</xref>].</p><p>Socio-economic level is recognized as a key environmental social factor because it has implications for access to resources that help individuals take care of themselves and others. Few studies have examined the association of socioeconomic level with CKD. One hundred and eighty-two patients (74.9%) had a low socioeconomic level compared to only six (2.4%) who were found in the high social class. The privileged reach of this socio-economic group could be explained by their frequent use of prohibited drugs from the parallel market and herbal medicine. But, also by the lack of medical follow-up of chronic diseases such as hypertension, this lack of money. Cruz et al. [<xref ref-type="bibr" rid="scirp.111352-ref14">14</xref>] find the existence of an inverse correlation between CKD, low education and low income. Our results agree with those of Ramilitiana et al. in 2009, in Antananarivo, in Madagascar who mentioned 65.6% of patients with a low socioeconomic level [<xref ref-type="bibr" rid="scirp.111352-ref15">15</xref>]. However, they differ from those of Houat Noria who reports in a study on the CKD in Algeria in 2014, 25% for the high socioeconomic level, 70% for the average socioeconomic level and only 5% for the low socioeconomic level [<xref ref-type="bibr" rid="scirp.111352-ref16">16</xref>]. The specified fast age of our sample did not eliminate the predominance of the lower socioeconomic class in the CKD but rather accentuated it, since Sumaili in Kinshasa; Ramilitiana in Antananarivo have certainly found high frequencies of low socio-economic level but at values lower than ours [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref15">15</xref>].</p><p>In our study a history of high blood pressure was found in 49.2% of patients. This high prevalence of hypertension is noted in all African studies [<xref ref-type="bibr" rid="scirp.111352-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]; it is probable the result of changes in environmental and behavioral determinants such as the consumption of tobacco, alcohol, lack of physical activity, an inadequate diet and obesity as well as prolonged periods of exposure to these determinants, but also due to renal fibrosis responsible for hypereninism [<xref ref-type="bibr" rid="scirp.111352-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref6">6</xref>]. The fight against CKD would begin by ensuring proper prevention of cardiovascular risk factors, especially hypertension, and their adequate management. Hypertension is an important cardiovascular risk factor and therefore an important renal risk factor. Indeed, it is the leading cause of CKD in Sub-Saharan Africa and is an important factor in the progression of CKD [<xref ref-type="bibr" rid="scirp.111352-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref15">15</xref>]. However, by comparing our data with those in the literature, its frequency is lower in children under 50 than in patients with CKD in general since less than half of our patients were hypertensive; while other studies of all ages report more than half of hypertension in CKD [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>].</p><p>Diabetes was the second antecedent found in 18.6% of patients. This prevalence of diabetes varies greatly from country to country and is also influenced by dietary and behavioral factors.</p><p>The mean serum creatinine clearance was 13.7 &#177; 26.2 ml/min/1.73m<sup>2</sup>. It was lower than that noted in Dakar by Ebata which was 19.95 ml/min/1.73m<sup>2</sup> [<xref ref-type="bibr" rid="scirp.111352-ref17">17</xref>]. A prevalence of 97.67% of chronic kidney failure was noted in our study. This rate is similar to that found in Dakar (97.8%) [<xref ref-type="bibr" rid="scirp.111352-ref17">17</xref>].</p><p>Due to its silent nature and the lack of awareness of kidney disease by the African population in general and by health personnel in particular, CKD is most often found at the end stage [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. Thus all the African data reveal a high frequency of CKD at the terminal stage [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. At stage 5 of CKD, Sumaili et al. found a frequency of 78%, Keylem et al. 75.3% [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. These 2 studies are carried out at all ages. Our study limited to patients under 50 years old confirms this African trend since 82.72% of CKD are at the end stage. The young age of less than 50 years does not change this tendency of stage 5 predominance.</p><p>In stage I where the CKD may be asymptomatic with normal renal function; only 3.7% of patients (n = 9) were found in our study. Sumaili et al. found 2% (n = 7) [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]; Keylem found 1.5% [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>]. These data confirm the silent evolution of CKD, as well as its ignorance and lack of routine health check-ups. The deficit of nephrologists, often forcing patients to travel long distances for a specialist consultation could also be responsible for the late diagnosis. In the West, where health coverage is almost complete and the number of nephrologists larger, studies show results totally opposite to ours [<xref ref-type="bibr" rid="scirp.111352-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref5">5</xref>].</p><p>The causes of CKD are diverse. The search for these requires a deep anamnestic investigation. This etiological research is not only limited to the clinic but also largely involves biological examinations, particularly immunology and histology after performing a renal puncture biopsy (RPB); this is when the stage of fibrosis suspected clinically and on renal ultrasound is not reached. Renal histology occupies an important place in the etiological diagnosis of CKD [<xref ref-type="bibr" rid="scirp.111352-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref3">3</xref>]. Indicated in 13 of our patients (5.3%), the frequency of indications for RPB was low in our sample. Renal puncture biopsy has not been performed in more than 3/4 of the patients who required it. These results could be explained by the weakness of our technical platform. In fact, the nephrology department of UHB does not have ultrasound machines or RPB guns. In addition, the many stains specific to renal histology and immunofluorescence are not available in our pathology laboratory. To the limits of the technical platform, we associate the high prevalence of stage 5 of CKD (55.1%), a practical contraindication to performing a RPB. All these data reflect the high number of undetermined nephropathies (55.1%). By comparing our data with those of the African literature, we also found a low frequency of performing RPB: Sumaili et al. in Kinshasa (DRC) performed a RPB en 13.1% of the patients collected in their study population [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. In Togo, Amekoudi etal., found no RPB performed in their patients due to lack of technical platform [<xref ref-type="bibr" rid="scirp.111352-ref18">18</xref>].</p><p>Hypertensive nephropathy was the leading cause of CKD (15.6%), followed by HIV-related nephropathy (13.6%) and diabetic nephropathy (13.2%). Hypertension has been described in the literature as the leading cause of CKD in black people [<xref ref-type="bibr" rid="scirp.111352-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref14">14</xref>]. Sumaili et al. found a predominance of nephroangiosclerosis in the order of (26.9%) [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]; Keylem et al. found 63.8% [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>]. The main cause of CKD in those under 50 is hypertension, contrasting with the study by DT Eyeni et al., carried out in the same department at all ages where the aetiologies were dominated by diabetes mellitus [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>].</p><p>While hypertension and diabetes mellitus have been presented in all African studies as the top two causes of CKD at any age [<xref ref-type="bibr" rid="scirp.111352-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref19">19</xref>]; our study limiting the age of patients to less than 50 years has particularly reversed this trend by putting HIV-related nephropathies in second place. Indeed, the HIV pandemic remains a topical issue with Africa as the most affected continent and young people as the most affected [<xref ref-type="bibr" rid="scirp.111352-ref20">20</xref>].</p><p>Segmental and focal hyalinosis was diagnosed in the two patients who had biopsy performed abroad. It is the primary cause of primary glomerulopathies in black subjects as reported by Segmental and focal hyalinosis, is reported by Sumaili et al. [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>].</p><p>Treatment for CKD depends on the etiology. At stage 5, management is based on dialysis while waiting for a kidney transplant. The latter remains the treatment par excellence for stage 5 of CKD [<xref ref-type="bibr" rid="scirp.111352-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref22">22</xref>]. In our study, the prevalence of stage 5 being high, there are therefore many indications for dialysis (n = 201 or 82.7%). However, the rate of accessibility to dialysis was low (25.3% of dialysis indications). This poor accessibility is explained on the one hand by the absence of a public dialysis center in Brazzaville [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>], and on the other hand by the high cost of a hemodialysis session in private centers [<xref ref-type="bibr" rid="scirp.111352-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>]. Our data join those of other African countries where access to dialysis is also difficult, particularly in Madagascar where only 1.2% of stage 5 patients have access to dialysis [<xref ref-type="bibr" rid="scirp.111352-ref15">15</xref>]. Kidney transplantation remains almost non-existent in Sub-Saharan Africa; with the exception of Abidjan, where the first kidney transplants in a country in Black Africa were performed in 2012 [<xref ref-type="bibr" rid="scirp.111352-ref23">23</xref>]. As in Kinshasa [<xref ref-type="bibr" rid="scirp.111352-ref13">13</xref>] and Ouagadougou [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>], in our study renal transplantation was not performed in any patient.</p><p>The death rate from CKD was high in our study (27.1%). The high prevalence of terminal CKD and the difficulties in accession replacement dialysis treatment could explain these results. Our data match those of: Keylem et al. in Ouagadougou (15 deaths or 21.7%) [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>].</p><p>The main cause of death found was severe acidosis, again reflecting the predominance of stage 5 in our sample.</p><p>Among the risk factors for death are: anemia, uremic encephalopathy, actute pulmonary edema reflecting severe acidosis (p-value &lt; 0.05). All these found risk factors for death are related to the severity of renal failure, thus reflecting delayed diagnosis of CKD but also difficult access to dialysis. Our results coincide with those of: Keylem et al. had found almost the same risk factors for death [<xref ref-type="bibr" rid="scirp.111352-ref12">12</xref>].</p><p>Otherwise, HIV infection also found as a risk factor for death; is considered a chronic systemic disease and can lead to many complications, including kidney damage. Since 2005, international companies (National Kidney Foundation) have recommended screening for kidney disease in all HIV-infected patients, the association of CRD with this is considered a factor of poor prognosis [<xref ref-type="bibr" rid="scirp.111352-ref24">24</xref>].</p>Limits of the Study<p>In assessing the extent of CKD in our study population, we were not spared from constraints. Indeed, the absence of certain medical files or certain key information made it impossible to use the data before 2016, thus justifying the small size of our sample. Also, the weakness of our technical platform was an obstacle to obtaining histological data, renal biopsies not being performed in our department during this study period. In addition, a prospective study would provide more details on the results.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The CKD of the young subject represents a concern in nephrology in Brazzaville because of its high frequency. The pathology concerns more the male sex and the patients consult the nephrology department late at stage 5 of the MRC. The predominant risk factors are represented by hypertension, HIV, diabetes mellitus and heart disease. Dialysis is indicated in the majority of cases but the rate of access to dialysis is low, due to the lack of a hemodialysis unit in public hospitals in Brazzaville, responsible for a high death rate. The prevention of cardiovascular risk factors and HIV is essential in our context, as it is the improvement of the technical platform.</p></sec><sec id="s6"><title>Contributions from Authors</title><p>All the authors mentioned have made their mark on the completion of this article.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The author declares no conflict of interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Sinomono, D.T.E., Sedan, G.N.-O., Mahoungou, G.H., Ngabe, E.P.G., Loumingou, R.M., Ellenga-Mbolla, B., Arrayhani, M. and Houssain, T.S. (2021) Epidemiological Clinical Profile of Chronic Kidney Disease in Adults under 50 at the University Hospital of Brazzaville. Open Journal of Nephrology, 11, 358-369. https://doi.org/10.4236/ojneph.2021.113029</p></sec></body><back><ref-list><title>References</title><ref id="scirp.111352-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jacquelinet, C. and Stengel, B. (2019) Chronic Kidney Disease. Elsevier, Amsterdam.</mixed-citation></ref><ref id="scirp.111352-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, A.D., Niamkey, E. and Yao, B.B. (1997) Chronic Renal Failure in C&amp;ocirc;te d’Ivoire: Study of 800 Hospital Cases. Public Health, 90, 346-348.</mixed-citation></ref><ref id="scirp.111352-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Coresh, J., Astor, B.C., Greene, T., et al. (2003) Prevalence of Chronic Kidney Disease and Decrease Kidney Function in the Adult US Population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases, 41, 1-12.https://doi.org/10.1053/ajkd.2003.50007</mixed-citation></ref><ref id="scirp.111352-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ahoui, S., Vigan, J., Albert, C., et al. (2016) Prevalence of Risk Factors for Chronic Kidney Disease in the Departments of Borgou and Alibori in Benin in 2014. Medicine and Public Health, 10, 1-12.</mixed-citation></ref><ref id="scirp.111352-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">HAS (2012) Guide to the Chronic Renal Disease Treatment Pathway in Adults 2012. https://www.has-sante.fr/jcms/c_1241102/fr/guide-parcours-de-soins-maladie-renale-chronique-of-the-adult</mixed-citation></ref><ref id="scirp.111352-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rabiller, J. and Faure, S. (2019) From Chronic Kidney Disease to Kidney Transplantation. Pharmaceutical News, 584, 20-25. https://doi.org/10.1016/j.actpha.2019.01.014</mixed-citation></ref><ref id="scirp.111352-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Pakasa, N.-M. and Suma&amp;iuml;li, E.-K. (2012) Anatomopathological Peculiarities of Renal Disease in the Subject of Sub-Saharan Africa: Synthetic Review of Data from the Democratic Republic of the Congo. Annals of Diagnostic Pathology, 32, 40-52.</mixed-citation></ref><ref id="scirp.111352-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Vimard, P. and Fassassi, R. (2012) Demography and Development in Africa: Retrospective and Prospective Elements. Cah Qué Demography, 40, 331-364.https://doi.org/10.7202/1011544ar</mixed-citation></ref><ref id="scirp.111352-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sinomono, D.T.E., Koumou, G.C. and Loumingou, R. (2017) Epidemiological Profile of Chronic Renal Failure at Brazzaville University Hospital in 2016. Therapeutic Nephrology, 13, 396. https://doi.org/10.1016/j.nephro.2017.08.302</mixed-citation></ref><ref id="scirp.111352-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Missamou, A., Sinomono, D.T.E., Loumingou, R., et al. (2019) Management of Renal Failure at the Pointe-Noire General Hospital in Congo: Between Realities and Hopes. Therapeutic Nephrology, 15, 344. https://doi.org/10.1016/j.nephro.2019.07.197</mixed-citation></ref><ref id="scirp.111352-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ngoie, S.M., Mulenga, P., Mukuku, O., et al. (2017) Chronic Renal Disease: Associated Factors, Etiologies, Clinical and Biological Characteristics in Lubumbashi in the Democratic Republic of Congo. The Pan African Medical Journal, 28, 1-11.</mixed-citation></ref><ref id="scirp.111352-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Keylem, C.G., Sempore, Y.W., Yameogo, A.A., et al. (2020) Diagnosis and Management of Chronic Kidney Disease in a Context of Limited Resources: Specificities and Difficulties of an Internal Medicine Department. African Journal of Internal Medicine, 7, 11-19.</mixed-citation></ref><ref id="scirp.111352-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sumaili, E.K., Krzesinski, J.-M., Cohen, E.P., et al. (2010) Epidemiology of Chronic Kidney Disease in the Democratic Republic of the Congo: A Synthetic Review of Studies from Kinshasa, the Capital. Therapeutic Nephrology, 6, 232-239.</mixed-citation></ref><ref id="scirp.111352-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cruz, I.A. and Hosten, A.O. (1989) An Update of the End-Stage Renal Disease Program at Howard University Hospital. Transplantation Proceedings, 21, 3892-3894.</mixed-citation></ref><ref id="scirp.111352-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ramilitiana, B., Ranivoharisoa, E.M., Dodo, M., et al. (2016) A Retrospective Study on the Incidence of Chronic Renal Failure in the Department of Internal Medicine and Nephrology of the University Hospital of Antananarivo. The Pan African Medical Journal, 23, 89-96. https://doi.org/10.11604/pamj.2016.23.141.8874</mixed-citation></ref><ref id="scirp.111352-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Houat, N., et al. (2017) Incidence of End-Stage Chronic Renal Failure in Maghnia. Santé Maghreb, 12, 8-14.</mixed-citation></ref><ref id="scirp.111352-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Seck, S., Ka, F. and Cisse, M. (2014) Prevalence Survey of Chronic Kidney Disease in the Northern Region of Senegal. Therapeutic Nephrology, 10, 399.https://doi.org/10.1016/j.nephro.2014.07.128</mixed-citation></ref><ref id="scirp.111352-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Amekoudi, E.Y., Sabi, K.A., Noto-Kadou-Kaza, B. and Combe, C. (2016) Epidemiology of Chronic Kidney Disease in Nephrology Consultation at the Sylvanus-Olympio CHU in Togo. Nephrology &amp; Therapeutics, 12, 400.https://doi.org/10.1016/j.nephro.2016.07.113</mixed-citation></ref><ref id="scirp.111352-ref19"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tiendrebéogo</surname><given-names> O. </given-names></name>,<etal>et al</etal>. (<year>2020</year>)<article-title>Epidemiology of Chronic Nephropathies in the Internal Medicine Department of the Yalgado Ouédraogo University Hospital Center (CHUYO) in Ouagadougou</article-title><source> African Journal of Internal Medicine</source><volume> 7</volume>,<fpage> 11</fpage>-<lpage>19</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.111352-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">UNAIDS, WHO and UNDP (2011) HIV/AIDS in Sub-Saharan Africa: An Update on the Epidemic and Health Sector Progress towards Universal Access. Situation Report.https://www.unaids.org/sites/default/files/media_asset/20111130_UA_Report_en_1.pdf</mixed-citation></ref><ref id="scirp.111352-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">National Kidney Foundation—Kidney Disease Outcomes Quality Initiative (NKFKD-OQI) (2002) Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Journal of American Kidney Disease, 39, 29-40.</mixed-citation></ref><ref id="scirp.111352-ref22"><label>22</label><mixed-citation publication-type="book" xlink:type="simple">El Nahas, M., Kawar, B.S. and El Kossi, M. (2012) Epidemiology, Etiology, Pathophysiology and Staging of Chronic Kidney Diseases. In: Edgar, V.L. and Allen, R.N., Eds., Nephrology Secrets, 3rd Edition, Elsevier, Amsterdam, 131-141.https://doi.org/10.1016/B978-1-4160-3362-2.00028-2</mixed-citation></ref><ref id="scirp.111352-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Coulibaly, N., Ackoundou-N’guessan, C., Nguessan, Y.F., Aye, Y., Guei, M.C., Toure, D.J.J., Hoang, A.D. and Sangare, I. (2016) Surgical Aspects and Preliminary Results of Renal Transplantation in C&amp;ocirc;te d’Ivoire. Uro’Andro, 1, 256-260.</mixed-citation></ref><ref id="scirp.111352-ref24"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Izzedine</surname><given-names> H. </given-names></name>,<etal>et al</etal>. (<year>2009</year>)<article-title>Renal Diseases during HIV Infection</article-title><source> Letter of Infectious Diseases</source><volume> 24</volume>,<fpage> 146</fpage>-<lpage>156</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref></ref-list></back></article>